Literature DB >> 1233245

A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man.

G Houin, J J Thébault, P D'Athis, J P Tillement, J L Beaumont.   

Abstract

A GLC method has been developed to measure chlorophenoxyisobutyric acid in plasma after benzol extraction and transformation to its methyl ester, using methyl laurate as the internal standard. Plasma free fatty acids did not interfere with the analysis, but it could not be employed in the presence of salicylates. The method has been employed to study the pharmacokinetics of chlorophenoxyisobutyric acid in man after oral ingestion of a single dose of clofibrate.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1233245     DOI： 10.1007/bf00562318

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  14 in total

1.  Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate.

Authors:  J M THROP
Journal:  Lancet       Date:  1962-06-23       Impact factor: 79.321

2.  Kinetics of drug absorption, distribution, metabolism, and excretion.

Authors:  E NELSON
Journal:  J Pharm Sci       Date:  1961-03       Impact factor: 3.534

3.  Anticoagulant effect and plasma kinetics of fluorophenindione after a single dose in man.

Authors:  J P Tillement; J J Thébault; C Mattei; P d'Athis; C Blatrix
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

4.  [Serum lipoproteins and antilipemic drugs related to clofibrate. Their in vitro interaction].

Authors:  J L Beaumont; C Dachet
Journal:  Atherosclerosis       Date:  1973 May-Jun       Impact factor: 5.162

5.  Studies on the mode of action of clofibrate: effects on hormone-induced changes in plasma free fatty acids, cholesterol, phospholipids and total esterified fatty acids in rats and dogs.

Authors:  A M Barrett; J M Thorp
Journal:  Br J Pharmacol Chemother       Date:  1968-02

6.  Plasma concentrations and bioavailability of clofibrate after administration to human subjects.

Authors:  L F Chasseaud; A J Cooper; V H Saggers
Journal:  J Clin Pharmacol       Date:  1974-07       Impact factor: 3.126

7.  Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters.

Authors:  J P Tillement; R Zini; P d' Athis; G Vassent
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

8.  Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination.

Authors:  J J Coffey; F J Bullock; P T Schoenemann
Journal:  J Pharm Sci       Date:  1971-11       Impact factor: 3.534

Review 9.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-26       Impact factor: 91.245

10.  FURTHER OBSERVATIONS ON THE EFFECTS OF ATROMID AND OF ETHYL CHLOROPHENOXYISOBUTYRATE ON SERUM LIPID LEVELS.

Authors:  M F OLIVER
Journal:  J Atheroscler Res       Date:  1963 Sep-Dec
View more
  9 in total

Review 1.  Clinical pharmacokinetics of hypolipidaemic drugs.

Authors:  R Gugler
Journal:  Clin Pharmacokinet       Date:  1978 Nov-Dec       Impact factor: 6.447

2.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

3.  Disposition pharmacokinetics of bezafibrate in man.

Authors:  U Abshagen; W Bablok; K Koch; P D Lang; H A Schmidt; M Senn; H Stork
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

4.  Lack of effect in vivo of clofibrate on adrenal steroid secretion.

Authors:  H M Heshmati; G Turpin; Y Touitou; J Varsaux; M Roger; K Nahoul; A Bogdan; A Auzeby
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

6.  Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.

Authors:  G Houin; R A Shastri; J Barre; B Pinchon; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid.

Authors:  W M Pardridge; D Casanello-Ertl; L Duducgian-Vartavarian
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

8.  Binding of tienilic acid (Diflurex) to human serum albumin and to plasma of normal subjects and uraemic patients.

Authors:  J Prandota; J P Tillement; P d'Athis; T Drüeke; S Digiulio
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

9.  Bioavailability of p-chlorophenoxyisobutyric acid (clofibrinic acid) after repeated doses of its calcium salt to humans.

Authors:  T Taylor; L F Chasseaud; A Darragh; D A O'Kelly
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.